VRTX Vertex Pharmaceuticals
Nasdaq · SEC CIK 875320 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $158.38M 53 sales by 13 insiders
- Filings on record
- 531 since 2021-07-16, latest 2026-09-10 16:31
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| Bozic Carmen | EVP, CMO | — | $11.31M |
| WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| Biller Jonathan | EVP, CLO | — | $4.08M |
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| Bunnage Mark E. | EVP, CSO | — | $3.00M |
Transactions 621
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-02-03 | 2022-02-01 | VRTX | Bozic Carmen | EVP, CMO | A - Grant | $0.00 | +24.0K | 56.9K | +73% | $0 |
| M | 2022-02-03 | 2022-02-01 | VRTX | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +38.4K | 79.5K | +93% | $0 |
| D | 2022-02-03 | 2022-02-02 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | M - OptEx | $86.52 | +4,660 | 70.4K | +7% | +$403.2K |
| DM | 2022-02-03 | 2022-02-02 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale+OE | $251.47 | -4,660 | 69.0K | -6% | -$1.17M |
| DM | 2022-02-03 | 2022-02-01 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | A - Grant | $0.00 | +32.1K | 65.7K | +96% | $0 |
| M | 2022-02-03 | 2022-02-01 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | A - Grant | $0.00 | +66.8K | 99.2K | +207% | $0 |
| 2022-02-03 | 2022-02-02 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | F - Tax | $243.63 | -6,279 | 110.3K | -5% | -$1.53M | |
| M | 2022-02-03 | 2022-02-01 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | A - Grant | $0.00 | +27.7K | 59.3K | +88% | $0 |
| 2022-02-03 | 2022-02-01 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $243.64 | -526 | 56.0K | -0.9% | -$128.2K | |
| M | 2022-02-03 | 2022-02-02 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $250.98 | -1,040 | 55.3K | -2% | -$261.0K |
| M | 2022-02-03 | 2022-02-01 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | A - Grant | $0.00 | +23.9K | 56.5K | +73% | $0 |
| 2022-02-03 | 2022-02-01 | VRTX | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +2,566 | 3,960 | +184% | $0 | |
| DM | 2022-02-01 | 2022-01-28 | VRTX | MCGLYNN MARGARET G | Dir | S - Sale+OE | $241.79 | -5,000 | 4,198 | -54% | -$1.21M |
| D | 2022-02-01 | 2022-01-28 | VRTX | MCGLYNN MARGARET G | Dir | M - OptEx | $127.54 | +5,000 | 6,099 | +455% | +$637.7K |
| M | 2021-11-16 | 2021-11-15 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $187.22 | -34 | 33.6K | -0.1% | -$6,365 |
| M | 2021-11-16 | 2021-11-15 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $187.26 | -3 | 41.1K | -0.0% | -$561.78 |
| M | 2021-11-16 | 2021-11-15 | VRTX | Sachdev Amit | EVP, Chief Patient Off | S - Sale | $187.19 | -51 | 31.9K | -0.2% | -$9,547 |
| 2021-11-03 | 2021-11-01 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $185.07 | -766 | 32.6K | -2% | -$141.8K | |
| M | 2021-08-23 | 2021-08-19 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | P - Purchase | $195.65 | +10.0K | 73.8K | +16% | +$1.96M |
| 2021-08-04 | 2021-08-02 | VRTX | SACHS BRUCE I | Dir | P - Purchase | $197.91 | +15.0K | 41.2K | +57% | +$2.97M | |
| 2021-08-03 | 2021-07-30 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $200.39 | -766 | 33.3K | -2% | -$153.5K |
Purchase Sale Sale after option exercise All abbreviations